Details of the Drug
General Information of Drug (ID: DMMO0SU)
| Drug Name |
Dersimelagon
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Dersimelagon; 1835256-48-8; Dersimelagon [INN]; Dersimelagon [USAN]; MT-7117; 1CWH5SV4G2; 1-(2-((3S,4R)-1-((3R,4R)-1-Cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl)-4-(methoxymethyl)pyrrolidin-3-yl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylic acid; Dersimelagon [USAN:INN]; UNII-1CWH5SV4G2; DERSIMELAGON [WHO-DD]; CHEMBL4802160; SCHEMBL18686769; MUNWOYRHJPWQNE-GMFUQMJFSA-N; WHO 10832; AKOS040746751; AC-36942; HY-109114; CS-0077733; 4-PIPERIDINECARBOXYLIC ACID, 1-(2-((3S,4R)-1-(((3R,4R)-1-CYCLOPENTYL-3-FLUORO-4-(4-METHOXYPHENYL)-3-PYRROLIDINYL)CARBONYL)-4-(METHOXYMETHYL)-3-PYRROLIDINYL)-5- (TRIFLUOROMETHYL)PHENYL)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecule
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Erythropoietic protoporphyria | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 5C58.12 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References


